Goldstein F W
Fondation Hôpital Saint-Joseph, 185 rue Raymond Losserand, 75014 Paris, France.
Clin Microbiol Infect. 2007 Jun;13 Suppl 2:2-6. doi: 10.1111/j.1469-0691.2007.01721.x.
The prevalence of antimicrobial resistance for both Gram-positive and Gram-negative pathogens is escalating worldwide. Outbreaks of community- and hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) are being reported more frequently. Although antimicrobial resistance is well recognised as a global problem, decisions about appropriate intervention and treatment should be made at the level of the local hospital or healthcare system. Thus, local surveillance to identify prevalent pathogens, detect bacterial resistance and identify particular strains is necessary for selecting optimal treatment regimens. In addition, bactericidal antimicrobial agents with novel mechanisms of action and activity against multidrug-resistant bacteria, together with improved infection control measures, are needed to address this growing medical problem more effectively.
全球范围内,革兰氏阳性菌和革兰氏阴性菌病原体的抗菌药物耐药性患病率都在不断上升。社区获得性和医院获得性耐甲氧西林金黄色葡萄球菌(MRSA)的暴发报告越来越频繁。尽管抗菌药物耐药性已被公认为一个全球性问题,但关于适当干预和治疗的决策应在当地医院或医疗系统层面做出。因此,进行本地监测以识别流行病原体、检测细菌耐药性并鉴定特定菌株,对于选择最佳治疗方案是必要的。此外,还需要具有新型作用机制且对多重耐药菌有效的杀菌抗菌药物,以及改进的感染控制措施,以更有效地应对这一日益严重的医学问题。